N4 PHARMA PLC — Remuneration Information 2016

Jun 9, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6621A

Evgen Pharma PLC

09 June 2016

For immediate release                                                                                                                            9 June 2016

Evgen Pharma plc

("Evgen Pharma" or the "Company")

Grant of Options

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 8 June 2016, David Chadwick, the Company's Senior Clinical Study Manager, was granted nil cost options over 53,473 ordinary shares exercisable for a period of ten years from the date of grant under the Evgen Long Term Incentive Plan ("LTIP").

The number of nil cost options awarded has been calculated by reference to the three month weighted average through to the closing market price on 7 June 2016.

These nil cost options will be subject to the rules of the LTIP and will vest in proportion to a Total Shareholder Return ("TSR") between the date of grant and the third anniversary of grant.

Enquiries:

Evgen Pharma plc	c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
www.evgen.com
Northland Capital Partners Limited	+44 (0) 20 3861 6625
Matthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance)
John Howes, Rob Rees (Corporate Broking)
Buchanan	+44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.  For further information please visit www.evgen.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCAKFDBABKDKAK